Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy language in Blueprint Medicines’ SEC documents can feel like decoding a genomic sequence. Pipeline updates on selective kinase therapies, milestone payments from collaborations, and cash-runway disclosures are scattered across hundreds of pages. If finding that information in a 10-K or spotting insider buys before an FDA catalyst seems daunting, you’re not alone.
Stock Titan solves the problem. Our platform delivers AI-powered summaries that translate complex biotech terminology into plain English, then links you straight to the source form. Need the Blueprint Medicines quarterly earnings report 10-Q filing? One click. Curious about Blueprint Medicines insider trading Form 4 transactions or real-time alerts for Blueprint Medicines Form 4 insider transactions real-time? We surface them instantly. From a Blueprint Medicines annual report 10-K simplified to a Blueprint Medicines 8-K material events explained, our AI highlights what moves the stock.
Here’s what you can do on this page:
- Review every 10-K, 10-Q and 8-K with side-by-side Blueprint Medicines earnings report filing analysis
- Track Blueprint Medicines executive stock transactions Form 4 and monitor patterns before clinical readouts
- Dive into the Blueprint Medicines proxy statement executive compensation to see how management is rewarded for pipeline milestones
- Use our natural-language search—“understanding Blueprint Medicines SEC documents with AI” returns plain-spoken answers, not PDFs
Every filing posts within minutes of hitting EDGAR, and our expert layer explains valuation drivers like clinical trial spend, collaboration revenue and patent updates. Complex biotech filings, now clear and actionable.
Blueprint Medicines Corporation (BPMC) director Jeffrey W. Albers received a significant equity grant on June 18, 2025. The transaction involved 3,902 restricted stock units (RSUs) awarded at a price of $128.12 per share.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents one share of common stock
- Following the transaction, Albers directly owns 150,532 shares
This Form 4 filing, signed by attorney-in-fact Melissa Masse on June 23, 2025, reflects standard director compensation practices and demonstrates continued alignment between board members and shareholder interests through equity-based compensation.
Blueprint Medicines Corp (BPMC) Director Mark Alan Goldberg received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, valued at $128.12 per share. Following this transaction, Goldberg directly owns 22,156 shares of common stock.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents the right to receive one share of common stock
- Total value of granted RSUs: approximately $500,000
This Form 4 filing, executed by attorney-in-fact Melissa Masse on June 23, 2025, represents standard equity compensation for a board member, aligning director interests with shareholders through stock ownership.
Blueprint Medicines Corp (BPMC) director Lynn Seely received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, with a value of $128.12 per unit. Following this transaction, Seely's direct ownership increased to 17,156 shares.
Key terms of the RSU grant:
- 100% vesting occurs at the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents a contingent right to receive one share of common stock
- Total grant value: approximately $500,000
This Form 4 filing, submitted by attorney-in-fact Melissa Masse on June 23, 2025, reflects standard director compensation practices through equity grants. The transaction was reported within the required SEC filing deadline of two business days.
Blueprint Medicines Director Daniella Beckman received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, with a value of $128.12 per unit, bringing her total direct holdings to 14,744 shares.
The RSUs have specific vesting terms: they will vest 100% on either June 18, 2026 or the next annual stockholder meeting, whichever occurs first. Each RSU represents the right to receive one share of common stock upon vesting.
This Form 4 filing, submitted by Attorney-in-Fact Melissa Masse on June 23, 2025, reflects standard equity compensation for a board member, indicating continued alignment between director and shareholder interests. The transaction was executed under regular compensation arrangements rather than through a Rule 10b5-1 trading plan.
Blueprint Medicines Corp (BPMC) director Alexis Borisy received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a price of $128.12 per share. Following this transaction, Borisy directly owns 78,062 shares of the company.
Key details of the RSU grant:
- Vesting occurs at 100% of underlying shares on the earlier of: - June 18, 2026 - Next annual stockholders' meeting
- Each RSU represents a contingent right to receive one share of common stock
- Transaction was reported via Form 4 filing on June 23, 2025
This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership.
Blueprint Medicines Director Habib J. Dable received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a reference price of $128.12 per share. Following this transaction, Dable directly owns 12,644 shares of the company.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents the right to receive one share of common stock upon vesting
- The transaction was reported via Form 4 filing, indicating changes in beneficial ownership
This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership. The filing was signed by Melissa Masse as attorney-in-fact on June 23, 2025.
Blueprint Medicines Corporation (BPMC) – Form 4 filed 23 Jun 2025
Director Lonnel Coats disclosed the award of 3,902 restricted stock units (RSUs) on 18 Jun 2025. Each RSU represents one share of common stock and vests 100 % on the earlier of 18 Jun 2026 or the company’s next annual meeting. No cash consideration was paid; the transaction is coded “A” (acquisition) and reflects routine director compensation rather than an open-market purchase.
Following the grant, Coats’ direct beneficial ownership increased to 6,144 BPMC shares, implying a net addition of 3,902 shares relative to his prior holding. No derivative securities, sales, or additional purchases were reported.
The filing is administrative in nature, providing insight into insider equity alignment but offering no new financial, operational, or strategic information about Blueprint Medicines. Investors may view the added ownership as modestly positive for governance alignment, yet the impact on valuation is likely immaterial.
Blueprint Medicines Corporation (BPMC) – SEC Form 4 Insider Transaction
Director John Tsai reported the receipt of 3,902 restricted stock units (RSUs) on 18 June 2025. Each RSU represents one share of BPMC common stock and vests 100 % on the earlier of 18 June 2026 or the company’s next annual shareholders’ meeting. The grant was recorded at an indicated price of $128.12 per share, a value reference supplied within the Form 4. Following the award, Tsai’s total direct beneficial ownership stands at 12,644 shares.
No open-market purchases or sales, option exercises, or derivative transactions were disclosed. The filing indicates a routine equity compensation grant intended to align the director’s interests with those of shareholders.
On 18 June 2025, Blueprint Medicines Corporation (Nasdaq: BPMC) reported the results of its 2025 Annual Meeting of Stockholders (Form 8-K, Item 5.07).
- Board elections: Class I directors Jeffrey W. Albers (44,683,223 for / 15,507,415 withheld ≈ 74%), Mark Goldberg, M.D. (46,734,594 / 13,456,044 ≈ 78%), and John Tsai, M.D. (47,572,890 / 12,617,748 ≈ 79%) were elected to three-year terms ending at the 2028 meeting.
- Say-on-pay: Executive compensation received strong support, passing with 57,714,069 votes for (≈96%), 2,450,825 against, and 25,744 abstentions.
- Auditor ratification: Ernst & Young LLP was re-appointed as independent auditor for FY 2025 with 62,209,853 votes for (≈99.5%), 288,580 against, and 34,861 abstentions.
No additional matters were presented. The filing is routine, reflecting continued shareholder endorsement of management and governance practices without introducing new strategic or financial information.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
What is Blueprint Medicines Corp focused on?
How does the company differentiate its approach in drug discovery?
What are the core therapeutic areas of Blueprint Medicines?
How does Blueprint Medicines generate revenue?
What is unique about their research and development process?
How does Blueprint Medicines address unmet medical needs?
What role do kinase inhibitors play in their treatment strategy?
How does the company maintain its market position?
